Sino Biopharm expands biosimilar ties: what it means for Sino Biopharm stock

Sino Biopharmaceutical Limited was last quoted at HKD 5.70 on the Hong Kong Stock Exchange at 10:03 a.m. HKT on October 7, 2026. The company entered a strategic biosimilar collaboration with STADA on September 28, 2026, according to Goodinvest.

Innovation revenue gains weight

For the six months ended June 30, 2026, Sino Biopharmaceutical reported revenue of RMB 19.44 billion, an increase of 10.60 percent from the same period a year earlier. Profit attributable to equity holders of the parent company reached RMB 3.43 billion, up 1.40 percent year on year, according to Moomoo.

Underlying profit rose 8.10 percent to RMB 3.34 billion in the same six-month period. Revenue from innovative drugs and out-licensing reached RMB 8.79 billion, up 44.30 percent year on year and equal to 45.20 percent of total revenue, the interim report said through Moomoo.

What the partnership means

The figures show why the STADA agreement matters: innovative medicines and licensing are expanding faster than the overall business, with 44.30 percent growth against 10.60 percent revenue growth in the first half of 2026. Management also announced an interim dividend of HKD 0.07 per share for that period, according to the interim report.

Analyst expectations provide a separate valuation reference. Nomura maintained a Buy rating and raised its price target from HKD 8.26 to HKD 8.67 on August 24, 2026, as reported by MarketScreener. That target is denominated in Hong Kong dollars and is separate from the euro reference used for German-market investors.

Stock and valuation markers

Sino Biopharmaceutical had a market capitalization of HKD 101.5 billion on October 7, 2026. Its 52-week range was HKD 4.19 to HKD 8.54, placing the HKD 5.70 quote below the period high while the company continues to build its innovative-drug pipeline.

Lang & Schwarz showed a prior close of EUR 0.66 dated October 6, 2026. The quote page also showed EUR 0.66 as the previous session reference, so no daily percentage change is carried into the article.

The further course of trading is shown by the continuously updated real-time quote of Sino Biopharm stock.

More news and analyses on Sino Biopharm stock